Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan
Open Access
- 1 February 2022
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 18, 363-373
Abstract
Aim: Anhedonia in major depressive disorder may be resistant to first-line antidepressants. We examined the effect of vortioxetine, a multimodal antidepressant, on anhedonia-like symptoms in Japanese patients with major depressive disorder. Methods: This was a post hoc analysis of an 8-week, randomized, double-blind, placebo-controlled, phase 3 study of vortioxetine (10 mg or 20 mg) in Japanese patients aged 20– 75 years with recurrent major depressive disorder and a Montgomery–Åsberg Depression Rating Scale (MADRS) total score of at least 26. The primary outcome was the mean change from baseline to week 8 in anhedonia-like symptoms as measured by MADRS anhedonia factor score, composed of: Q1, apparent sadness; Q2, reported sadness; Q6, concentration; Q7, lassitude; and Q8, inability to feel. Mean change in MADRS total score and anhedonia factor score were compared among treatment groups, with data categorized by median baseline anhedonia factor score (0– 17 or ≥ 18). Results: Data were available for 489 patients. The least-squares mean difference in MADRS anhedonia factor score change from baseline to week 8 versus placebo was − 1.34 for vortioxetine 10 mg (P = 0.0300) and − 1.77 for vortioxetine 20 mg (P = 0.0044). The least-squares mean difference between vortioxetine and placebo in MADRS total score change from baseline to week 8 was − 3.11 (10 mg dose) and − 3.37 (20 mg dose) for patients with a higher baseline anhedonia factor score (≥ 18), and − 2.08 (10 mg) and − 2.61 (20 mg) for patients with a lower baseline score (0– 17). Conclusion: This post hoc analysis suggests that vortioxetine may have therapeutic potential in patients with anhedonia-like symptoms of major depressive disorder. ClinicalTrials.gov identifier for primary study: NCT02389816.Keywords
This publication has 48 references indexed in Scilit:
- Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive DisorderJournal of Clinical Psychopharmacology, 2012
- Anhedonia Predicts Poorer Recovery Among Youth With Selective Serotonin Reuptake Inhibitor Treatment–Resistant DepressionJournal of the American Academy of Child & Adolescent Psychiatry, 2012
- Anhedonia and major depression: The role of agomelatineEuropean Neuropsychopharmacology, 2012
- Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptomsPsychological Medicine, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Reconsidering anhedonia in depression: Lessons from translational neuroscienceNeuroscience & Biobehavioral Reviews, 2011
- Anhedonia in Unipolar Major Depressive Disorder: A Review~!2009-10-26~!2010-02-18~!2010-04-08~!The Open Psychiatry Journal, 2010
- Effect of aripiprazole on self-reported anhedonia in bipolar depressed patientsPsychiatry Research, 2009
- A three‐factor analytic model of the MADRS in geriatric depressionInternational Journal of Geriatric Psychiatry, 2002
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979